Neuropeptide Y and Sympathovagal Balance

Summary

Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and Y2 receptors. This double-blind placebo-controlled crossover study investigated the sympathovagal balance during three exercises on a cycloergometer in healthy volunteers treated with saxagliptin (DPP4 inhibitor).

Conditions

• Physical Activity
• Sympathetic Nervous System
• Secretion; Catecholamine

Interventions

DRUG

Saxagliptin 5mg

Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin

DRUG

Placebo oral capsule

Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin

OTHER

ergometric test in healthy volunteers

The volunteers will undergo an ergometric test in each session

Sponsors & Collaborators

• grégoire wuerzner

  collaborator UNKNOWN

• grégoire millet

  collaborator UNKNOWN

• Nicolas Bourdillon

  collaborator UNKNOWN

• Philippe Eugster

  collaborator UNKNOWN

• Eric Grouzmann

  lead OTHER

Principal Investigators

• Eric Grouzmann, Dr · Centre Hospitalier Universitaire Vaudois

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Model

CROSSOVER

Eligibility

Min Age

24 Years

Max Age

30 Years

Sex

MALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2018-06-05

Primary Completion

2018-07-18

Completion

2019-04-15

Countries

• Switzerland

Study Locations